Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Editorial Volume 6 Issue 1

Routes of Antibody Drug Delivery and Challenges

Wenqiang Liu*

Hengenix Biotech, Inc., Milpitas, CA, United States

*Corresponding Author: Wenqiang Liu, Hengenix Biotech, Inc., Milpitas, CA, United States.

Received: November 22, 2021; Published: December 01, 2021


Antibody drugs have become the most rapidly growing marketed drug products within recent years. During January 1 to November 12, 2021, 11 antibody therapeutics were granted first approval in either the US or EU. And as of November 12, 2021, 18 investigational antibody therapeutics are in regulatory review in either the US or EU. More than 130 antibody drug products have been approved globally until today, of which most are in liquid solutions and ~27% are lyophilized powders. Antibody therapies are usually highly specific to their targets and with better safety profile comparing to traditional small-molecule drugs. However, antibody-based drugs usually have short pharmacokinetic properties (couple days to weeks), low tissue penetration, and stability issues during manufacturing, transport, storage, and formulation which limit their clinical use. The routes of administration are mainly subcutaneous or intravenous infusion with several intravenous bolus, intravitreal, and intramuscular in drug products so far. There are many opportunities in developing antibody formulations and delivery systems for better patient compliance, cost savings and lifecycle management.


Citation: Wenqiang Liu. “Routes of Antibody Drug Delivery and Challenges". Acta Scientific Pharmaceutical Sciences 6.1 (2022): 01-02.


Copyright: © 2022 Wenqiang Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate32%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 30th, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US